

Experiment Number: 03039 - 02

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 12/04/2020

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

NTP Study Number: C03039B
Lock Date: 12/18/2017
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 3.0.2.3_002
PWG Approval Date: 10/13/2017

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
------------------	--------------	--------------	--------------	--------------	--------------	--------------

Disposition Summary

Animals Initially In Study	48	48	48	48	48	48
Early Deaths						
Accidentally Killed	1					
Moribund	10	18	11	14	18	16
Natural Death	1		2	3	1	
Survivors						
Moribund	1		1		1	1
Terminal Sacrifice	35	30	34	31	28	31
Animals Examined Microscopically	48	48	48	48	48	48

ALIMENTARY SYSTEM

Esophagus	(48)	(48)	(48)	(48)	(48)	(48)
Gallbladder	(45)	(44)	(43)	(41)	(40)	(46)
Intestine Large, Cecum	(47)	(48)	(46)	(46)	(47)	(48)
Adenocarcinoma			1 (2%)			
Adenoma				1 (2%)		
Intestine Large, Colon	(48)	(48)	(46)	(46)	(48)	(48)
Adenocarcinoma			1 (2%)			
Intestine Large, Rectum	(47)	(48)	(46)	(46)	(48)	(48)
Intestine Small, Duodenum	(47)	(48)	(46)	(46)	(47)	(48)
Adenocarcinoma	1 (2%)			1 (2%)		
Intestine Small, Ileum	(47)	(48)	(46)	(46)	(47)	(48)
Intestine Small, Jejunum	(47)	(48)	(46)	(46)	(47)	(48)
Adenocarcinoma			1 (2%)	2 (4%)		1 (2%)
Adenoma						1 (2%)
Liver	(48)	(48)	(48)	(48)	(48)	(48)
Hemangiosarcoma	4 (8%)	1 (2%)	2 (4%)	5 (10%)	4 (8%)	3 (6%)
Hepatoblastoma	2 (4%)	1 (2%)				1 (2%)
Hepatocellular Adenoma	9 (19%)	9 (19%)	11 (23%)	10 (21%)	14 (29%)	9 (19%)
Hepatocellular Adenoma, Multiple	16 (33%)	21 (44%)	23 (48%)	16 (33%)	17 (35%)	17 (35%)
Hepatocellular Carcinoma	14 (29%)	11 (23%)	16 (33%)	24 (50%)	19 (40%)	21 (44%)
Hepatocellular Carcinoma, Multiple	1 (2%)	6 (13%)	4 (8%)	3 (6%)	6 (13%)	6 (13%)
Hepatocholangiocarcinoma					2 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Mesentery	(2)	(1)	(3)	(1)	(5)	(2)
Hepatocarcinoma, Metastatic, Liver					1 (20%)	
Sarcoma	2 (100%)					
Pancreas	(48)	(48)	(48)	(47)	(48)	(48)
Fibrous Histiocytoma						1 (2%)
Salivary Glands	(48)	(48)	(48)	(48)	(48)	(48)
Schwannoma Malignant		1 (2%)				
Stomach, Forestomach	(48)	(48)	(48)	(47)	(48)	(48)
Squamous Cell Carcinoma		1 (2%)				
Squamous Cell Papilloma			1 (2%)			
Stomach, Glandular	(48)	(48)	(46)	(46)	(48)	(48)
Adenoma	1 (2%)					
Tongue	(0)	(0)	(0)	(1)	(0)	(0)
CARDIOVASCULAR SYSTEM						
Blood Vessel	(48)	(48)	(47)	(48)	(48)	(48)
Hepatocarcinoma, Metastatic, Liver					1 (2%)	
Heart	(48)	(48)	(48)	(48)	(48)	(48)
Hepatocarcinoma, Metastatic, Liver					2 (4%)	
ENDOCRINE SYSTEM						
Adrenal Cortex	(47)	(48)	(48)	(47)	(47)	(48)
Hepatocarcinoma, Metastatic, Liver					1 (2%)	
Subcapsular, Adenoma	2 (4%)	4 (8%)	1 (2%)	1 (2%)	3 (6%)	
Adrenal Medulla	(47)	(47)	(48)	(47)	(46)	(48)
Pheochromocytoma Benign						1 (2%)
Pheochromocytoma Malignant					1 (2%)	1 (2%)
Islets, Pancreatic	(48)	(48)	(48)	(47)	(48)	(47)
Adenoma	1 (2%)	1 (2%)				
Carcinoma						1 (2%)
Parathyroid Gland	(41)	(46)	(46)	(44)	(44)	(45)
Pituitary Gland	(48)	(46)	(46)	(47)	(46)	(45)
Thyroid Gland	(48)	(48)	(48)	(47)	(48)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Follicular Cell, Carcinoma			1 (2%)			
GENERAL BODY SYSTEM						
Tissue NOS	(0)	(0)	(0)	(0)	(2)	(0)
Hepatocarcinoma, Metastatic, Liver					1 (50%)	
GENITAL SYSTEM						
Epididymis	(48)	(48)	(48)	(48)	(48)	(48)
Fibrous Histiocytoma						1 (2%)
Fat Pad, Epididymal	(0)	(0)	(0)	(1)	(1)	(0)
Hepatocarcinoma, Metastatic, Liver					1 (100%)	
Preputial Gland	(48)	(48)	(48)	(48)	(48)	(48)
Prostate	(48)	(48)	(48)	(47)	(48)	(48)
Fibrous Histiocytoma						1 (2%)
Hepatocarcinoma, Metastatic, Liver					1 (2%)	
Seminal Vesicle	(48)	(48)	(46)	(46)	(48)	(48)
Fibrous Histiocytoma						1 (2%)
Testes	(48)	(48)	(47)	(48)	(48)	(48)
HEMATOPOIETIC SYSTEM						
Bone Marrow	(48)	(48)	(48)	(47)	(48)	(48)
Hemangiosarcoma			1 (2%)		2 (4%)	
Lymph Node	(2)	(3)	(4)	(3)	(2)	(2)
Pancreatic, Fibrous Histiocytoma						1 (50%)
Renal, Fibrous Histiocytoma						1 (50%)
Lymph Node, Mandibular	(47)	(46)	(48)	(48)	(48)	(47)
Neuroblastoma Malignant, Metastatic, Brain, Cerebrum					1 (2%)	
Lymph Node, Mesenteric	(48)	(48)	(47)	(47)	(48)	(47)
Fibrous Histiocytoma						1 (2%)
Hemangiosarcoma	1 (2%)		1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Hepatocolangiocarcinoma, Metastatic, Liver					1 (2%)	
Spleen	(47)	(48)	(48)	(47)	(48)	(48)
Fibrous Histiocytoma						1 (2%)
Hemangiosarcoma	1 (2%)	4 (8%)	3 (6%)		4 (8%)	3 (6%)
Thymus	(46)	(44)	(46)	(43)	(44)	(48)
Hepatocolangiocarcinoma, Metastatic, Liver					1 (2%)	
INTEGUMENTARY SYSTEM						
Mammary Gland	(1)	(2)	(0)	(2)	(2)	(0)
Skin	(48)	(48)	(48)	(48)	(48)	(48)
Fibrous Histiocytoma		1 (2%)				
Subcutaneous Tissue, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)		
Subcutaneous Tissue, Fibrosarcoma		2 (4%)				1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma	1 (2%)					
Subcutaneous Tissue, Hemangiosarcoma			1 (2%)			1 (2%)
Subcutaneous Tissue, Lipoma					1 (2%)	
Skin, Control	(48)	(48)	(48)	(48)	(48)	(48)
Skin, Site Of Application	(48)	(48)	(48)	(48)	(48)	(48)
MUSCULOSKELETAL SYSTEM						
Bone	(0)	(1)	(1)	(0)	(3)	(0)
Cranium, Sarcoma, Deep Invasion		1 (100%)				
Vertebra, Hepatocolangiocarcinoma, Metastatic, Liver					1 (33%)	
Bone, Femur	(48)	(48)	(48)	(48)	(48)	(48)
Hemangiosarcoma					1 (2%)	
Osteosarcoma		1 (2%)				
Skeletal Muscle	(0)	(2)	(1)	(0)	(4)	(0)
Fibrosarcoma, Deep Invasion		1 (50%)				
Hemangiosarcoma					2 (50%)	
Hepatocolangiocarcinoma, Metastatic, Liver					2 (50%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
NERVOUS SYSTEM						
Brain, Brain Stem	(48)	(48)	(48)	(48)	(48)	(48)
Neuroblastoma Malignant					1 (2%)	
Brain, Cerebellum	(48)	(48)	(48)	(48)	(48)	(48)
Brain, Cerebrum	(48)	(48)	(48)	(48)	(48)	(48)
Meninges, Sarcoma		1 (2%)				
Olfactory Lobe, Neuroblastoma Malignant					1 (2%)	
Nerve Trigeminal	(0)	(1)	(1)	(0)	(0)	(0)
Peripheral Nerve, Sciatic	(0)	(1)	(1)	(0)	(0)	(0)
Spinal Cord, Cervical	(0)	(1)	(1)	(0)	(0)	(0)
Spinal Cord, Lumbar	(0)	(1)	(1)	(0)	(0)	(0)
Spinal Cord, Thoracic	(0)	(1)	(1)	(0)	(0)	(0)

RESPIRATORY SYSTEM

Lung	(48)	(48)	(48)	(48)	(48)	(48)
Alveolar/Bronchiolar Adenoma	5 (10%)	5 (10%)	5 (10%)	6 (13%)	2 (4%)	5 (10%)
Alveolar/Bronchiolar Adenoma, Multiple	1 (2%)					
Alveolar/Bronchiolar Carcinoma	2 (4%)	5 (10%)	1 (2%)	3 (6%)	2 (4%)	3 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple		1 (2%)				1 (2%)
Hemangiosarcoma					1 (2%)	
Hepatoblastoma, Metastatic, Liver		1 (2%)				
Hepatocellular Carcinoma, Metastatic, Liver	6 (13%)	6 (13%)	3 (6%)	6 (13%)	4 (8%)	6 (13%)
Hepatocholangiocarcinoma, Metastatic, Liver					2 (4%)	
Osteosarcoma, Metastatic, Bone, Femur		1 (2%)				
Sarcoma				1 (2%)		
Schwannoma Malignant, Metastatic, Salivary Glands		1 (2%)				
Bronchiole, Adenoma			1 (2%)			
Nose	(48)	(48)	(48)	(48)	(48)	(48)
Neuroblastoma Malignant					1 (2%)	
Adventitia, Hepatocholangiocarcinoma, Metastatic, Liver					1 (2%)	
Trachea	(48)	(48)	(48)	(47)	(48)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
SPECIAL SENSES SYSTEM						
Eye	(47)	(48)	(44)	(47)	(48)	(47)
Hepatocholangiocarcinoma, Metastatic, Liver Lids, Adenoma		1 (2%)			1 (2%)	
Harderian Gland	(48)	(48)	(48)	(47)	(48)	(48)
Adenoma	1 (2%)	4 (8%)	4 (8%)	4 (9%)	6 (13%)	5 (10%)
URINARY SYSTEM						
Kidney	(48)	(48)	(48)	(47)	(48)	(48)
Adenoma			2 (4%)			1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)		
Fibrous Histiocytoma						1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver					2 (4%)	
Urinary Bladder	(48)	(48)	(48)	(47)	(48)	(48)
SYSTEMIC LESIONS						
Multiple Organ	*(48)	*(48)	*(48)	*(48)	*(48)	*(48)
Histiocytic Sarcoma					1 (2%)	1 (2%)
Lymphoma Malignant	3 (6%)	1 (2%)	4 (8%)	2 (4%)	1 (2%)	1 (2%)
Mast Cell Tumor Malignant		1 (2%)	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
------------------	--------------	--------------	--------------	--------------	--------------	--------------

Tumor Summary for Males

Total Animals with Primary Neoplasms (b)	41	42	44	43	45	43
Total Primary Neoplasms	68	85	86	79	92	93
Total Animals with Benign Neoplasms	31	35	37	31	37	29
Total Benign Neoplasms	36	45	48	38	43	39
Total Animals with Malignant Neoplasms	25	31	26	32	33	35
Total Malignant Neoplasms	32	40	38	41	49	54
Total Animals with Metastatic Neoplasms	6	9	3	6	7	6
Total Metastatic Neoplasms	6	9	3	8	24	6
Total Animals with Malignant Neoplasms Uncertain Primary Site						
Total Animals with Neoplasms Uncertain- Benign or Malignant						
Total Uncertain Neoplasms						

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
--------------------	----------------	----------------	----------------	----------------	----------------	----------------

Disposition Summary

Animals Initially In Study	48	48	48	48	48	48
Early Deaths						
Moribund	11	17	17	14	8	10
Natural Death	1	1			3	2
Survivors						
Moribund	1	1		1		1
Terminal Sacrifice	35	29	31	33	37	35
Animals Examined Microscopically	48	48	48	48	48	48

ALIMENTARY SYSTEM

Esophagus	(48)	(48)	(48)	(48)	(48)	(48)
Gallbladder	(45)	(46)	(44)	(47)	(45)	(44)
Intestine Large, Cecum	(47)	(48)	(48)	(48)	(45)	(46)
Hepatocolangiocarcinoma, Metastatic, Liver			1 (2%)			
Leiomyoma		1 (2%)				
Leiomyosarcoma					1 (2%)	
Intestine Large, Colon	(47)	(47)	(48)	(48)	(45)	(46)
Intestine Large, Rectum	(47)	(48)	(48)	(48)	(45)	(46)
Anus, Sarcoma		1 (2%)				
Intestine Small, Duodenum	(47)	(47)	(48)	(48)	(45)	(46)
Adenoma	1 (2%)					
Intestine Small, Ileum	(47)	(48)	(48)	(48)	(45)	(46)
Intestine Small, Jejunum	(47)	(48)	(48)	(48)	(45)	(46)
Adenocarcinoma			1 (2%)			
Liver	(48)	(48)	(48)	(48)	(48)	(48)
Hemangiosarcoma		1 (2%)		1 (2%)		
Hepatocellular Adenoma	12 (25%)	8 (17%)	9 (19%)	11 (23%)	9 (19%)	12 (25%)
Hepatocellular Adenoma, Multiple	5 (10%)	5 (10%)	8 (17%)	11 (23%)	9 (19%)	5 (10%)
Hepatocellular Carcinoma	10 (21%)	6 (13%)	8 (17%)	10 (21%)	6 (13%)	7 (15%)
Hepatocellular Carcinoma, Multiple			1 (2%)	2 (4%)	2 (4%)	
Hepatocolangiocarcinoma			1 (2%)		1 (2%)	
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
Mesentery	(7)	(4)	(11)	(14)	(8)	(6)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (25%)				
Hepatocolangiocarcinoma, Metastatic, Liver			1 (9%)		1 (13%)	
Pancreas	(48)	(48)	(48)	(48)	(48)	(48)
Hepatocolangiocarcinoma, Metastatic, Liver			1 (2%)			
Sarcoma Stromal, Metastatic, Uterus			1 (2%)			
Salivary Glands	(48)	(48)	(48)	(48)	(48)	(48)
Stomach, Forestomach	(48)	(48)	(48)	(48)	(48)	(48)
Squamous Cell Carcinoma	1 (2%)					
Squamous Cell Papilloma		2 (4%)		1 (2%)		1 (2%)
Stomach, Glandular	(47)	(48)	(48)	(48)	(45)	(46)
Polyp Adenomatous		1 (2%)				
Tongue	(0)	(0)	(0)	(0)	(0)	(1)
CARDIOVASCULAR SYSTEM						
Blood Vessel	(48)	(48)	(48)	(48)	(48)	(48)
Heart	(48)	(48)	(48)	(48)	(48)	(48)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)				
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
ENDOCRINE SYSTEM						
Adrenal Cortex	(48)	(48)	(48)	(48)	(48)	(48)
Adenoma		1 (2%)				
Hepatocolangiocarcinoma, Metastatic, Liver			1 (2%)			
Osteosarcoma, Metastatic, Bone, Femur			1 (2%)			
Sarcoma Stromal, Metastatic, Uterus			1 (2%)			
Subcapsular, Adenoma	1 (2%)			2 (4%)		
Adrenal Medulla	(48)	(48)	(48)	(47)	(48)	(48)
Pheochromocytoma Benign		1 (2%)		2 (4%)		
Pheochromocytoma Malignant		1 (2%)		1 (2%)		1 (2%)
Islets, Pancreatic	(48)	(48)	(48)	(48)	(48)	(48)
Adenoma	1 (2%)					3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Carcinoma	1 (2%)			1 (2%)		
Parathyroid Gland	(44)	(45)	(45)	(43)	(45)	(43)
Pituitary Gland	(47)	(47)	(47)	(47)	(46)	(46)
Pars Distalis, Adenoma		1 (2%)	1 (2%)	2 (4%)	2 (4%)	1 (2%)
Pars Intermedia, Adenoma						1 (2%)
Thyroid Gland	(48)	(48)	(48)	(48)	(48)	(48)
Follicular Cell, Adenoma				2 (4%)		
GENERAL BODY SYSTEM						
Tissue NOS	(0)	(3)	(2)	(1)	(0)	(1)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (33%)				
Hepatocolangiocarcinoma, Metastatic, Liver			1 (50%)			
GENITAL SYSTEM						
Clitoral Gland	(46)	(44)	(45)	(45)	(45)	(43)
Fat Pad, Ovarian/parametrial	(0)	(0)	(1)	(0)	(0)	(0)
Hepatocolangiocarcinoma, Metastatic, Liver			1 (100%)			
Ovary	(48)	(48)	(48)	(48)	(48)	(48)
Cystadenocarcinoma						1 (2%)
Cystadenoma	4 (8%)	5 (10%)	2 (4%)	1 (2%)	1 (2%)	
Granulosa Cell Tumor Benign			1 (2%)			
Granulosa Cell Tumor Malignant	1 (2%)					
Luteoma		1 (2%)	1 (2%)	2 (4%)		
Sarcoma Stromal, Metastatic, Uterus			1 (2%)			
Uterus	(48)	(48)	(48)	(48)	(48)	(48)
Carcinoma				1 (2%)		
Hemangioma						1 (2%)
Hemangiosarcoma			1 (2%)			
Hepatocolangiocarcinoma, Metastatic, Liver			1 (2%)			
Leiomyoma			1 (2%)			
Leiomyosarcoma		1 (2%)				
Polyp Stromal	4 (8%)	1 (2%)	3 (6%)	4 (8%)	1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
Sarcoma Stromal	1 (2%)		1 (2%)	1 (2%)	1 (2%)	
Schwannoma Malignant				1 (2%)		
Endometrium, Adenocarcinoma	1 (2%)		1 (2%)	2 (4%)		
Endometrium, Adenoma				1 (2%)		
HEMATOPOIETIC SYSTEM						
Bone Marrow	(47)	(48)	(48)	(48)	(48)	(48)
Hemangiosarcoma			1 (2%)			
Osteosarcoma			1 (2%)			
Lymph Node	(7)	(4)	(8)	(6)	(2)	(6)
Axillary, Sarcoma, Metastatic, Uncertain Primary Site				1 (17%)		
Lumbar, Sarcoma, Metastatic, Uncertain Primary Site				1 (17%)		
Mediastinal, Hepatocholangiocarcinoma, Metastatic, Liver			1 (13%)			
Renal, Sarcoma, Metastatic, Uncertain Primary Site				1 (17%)		
Lymph Node, Mandibular	(47)	(48)	(48)	(48)	(48)	(47)
Lymph Node, Mesenteric	(48)	(47)	(46)	(48)	(46)	(48)
Fibrous Histiocytoma	1 (2%)					
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
Spleen	(48)	(48)	(48)	(48)	(48)	(48)
Hemangiosarcoma	1 (2%)		1 (2%)	1 (2%)	1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)			
Sarcoma Stromal, Metastatic, Uterus			1 (2%)			
Thymus	(47)	(46)	(48)	(48)	(48)	(48)
INTEGUMENTARY SYSTEM						
Mammary Gland	(47)	(48)	(46)	(46)	(47)	(47)
Skin	(48)	(48)	(48)	(48)	(48)	(48)
Basosquamous Tumor Malignant					1 (2%)	
Fibrous Histiocytoma	1 (2%)		1 (2%)	1 (2%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Subcutaneous Tissue, Fibrosarcoma	1 (2%)		1 (2%)	1 (2%)		1 (2%)
Subcutaneous Tissue, Hemangioma			1 (2%)			
Subcutaneous Tissue, Hemangiosarcoma				1 (2%)		
Subcutaneous Tissue, Liposarcoma			1 (2%)			
Subcutaneous Tissue, Osteoma						1 (2%)
Subcutaneous Tissue, Sarcoma		2 (4%)	1 (2%)			
Skin, Control	(48)	(48)	(48)	(48)	(48)	(48)
Subcutaneous Tissue, Fibrosarcoma				1 (2%)		
Skin, Site Of Application	(48)	(48)	(48)	(48)	(48)	(48)
MUSCULOSKELETAL SYSTEM						
Bone	(0)	(1)	(0)	(0)	(1)	(0)
Cranium, Osteosarcoma					1 (100%)	
Pelvis, Osteosarcoma		1 (100%)				
Bone, Femur	(48)	(48)	(48)	(48)	(48)	(48)
Osteosarcoma			1 (2%)			
Skeletal Muscle	(1)	(2)	(2)	(3)	(0)	(0)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (50%)				
Hepatocholangiocarcinoma, Metastatic, Liver			1 (50%)			
Myxosarcoma	1 (100%)					
Rhabdomyosarcoma				1 (33%)		
Sarcoma, Metastatic, Uncertain Primary Site				1 (33%)		
Sarcoma, Deep Invasion		1 (50%)				
NERVOUS SYSTEM						
Brain, Brain Stem	(48)	(48)	(48)	(48)	(48)	(48)
Brain, Cerebellum	(48)	(48)	(48)	(48)	(48)	(48)
Osteosarcoma, Metastatic, Bone					1 (2%)	
Brain, Cerebrum	(48)	(48)	(48)	(48)	(48)	(48)
Nerve Trigeminal	(0)	(0)	(1)	(1)	(0)	(0)
Peripheral Nerve, Sciatic	(0)	(0)	(1)	(1)	(0)	(0)
Spinal Cord	(0)	(0)	(0)	(1)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Sarcoma, Metastatic, Uncertain Primary Site				1 (100%)		
Spinal Cord, Cervical	(0)	(0)	(1)	(1)	(0)	(0)
Spinal Cord, Lumbar	(0)	(0)	(1)	(1)	(0)	(0)
Spinal Cord, Thoracic	(0)	(0)	(1)	(1)	(0)	(0)

RESPIRATORY SYSTEM

Lung	(48)	(48)	(48)	(48)	(48)	(48)
Alveolar/Bronchiolar Adenoma	3 (6%)	4 (8%)	4 (8%)	3 (6%)	4 (8%)	1 (2%)
Alveolar/Bronchiolar Carcinoma		2 (4%)			2 (4%)	1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)	1 (2%)	3 (6%)	1 (2%)	2 (4%)	2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)		1 (2%)	
Osteosarcoma, Metastatic, Bone		1 (2%)				
Osteosarcoma, Metastatic, Bone, Femur			1 (2%)			
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
Nose	(48)	(48)	(48)	(48)	(48)	(48)
Osteosarcoma, Metastatic, Bone, Femur			1 (2%)			
Trachea	(48)	(48)	(48)	(48)	(48)	(48)

SPECIAL SENSES SYSTEM

Eye	(47)	(46)	(48)	(48)	(45)	(46)
Melanoma Malignant				1 (2%)		
Harderian Gland	(48)	(48)	(47)	(48)	(48)	(47)
Adenocarcinoma				2 (4%)		
Adenoma	12 (25%)	4 (8%)	2 (4%)	2 (4%)	4 (8%)	2 (4%)
Zymbal's Gland	(0)	(1)	(1)	(0)	(0)	(0)
Squamous Cell Carcinoma		1 (100%)				
Squamous Cell Papilloma			1 (100%)			

URINARY SYSTEM

Kidney	(48)	(48)	(48)	(48)	(48)	(48)
Adenoma	1 (2%)					1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)				
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)		1 (2%)	
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
Urinary Bladder	(48)	(48)	(48)	(48)	(48)	(47)
SYSTEMIC LESIONS						
Multiple Organ	*(48)	*(48)	*(48)	*(48)	*(48)	*(48)
Histiocytic Sarcoma	1 (2%)	5 (10%)	3 (6%)		1 (2%)	1 (2%)
Leukemia Erythrocytic						1 (2%)
Leukemia Granulocytic	1 (2%)				1 (2%)	
Lymphoma Malignant	7 (15%)	4 (8%)	6 (13%)	6 (13%)	2 (4%)	9 (19%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Triclosan

Time Report Requested: 13:42:33

Route: Dermal

CAS Number: 3380-34-5

First Dose M/F: 09/11/13 / 09/11/13

Species/Strain: MICE/B6C3F1

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
--------------------	----------------	----------------	----------------	----------------	----------------	----------------

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	41	35	41	37	34	38
Total Primary Neoplasms	73	61	65	79	51	52
Total Animals with Benign Neoplasms	29	25	26	30	24	24
Total Benign Neoplasms	44	35	34	44	30	30
Total Animals with Malignant Neoplasms	25	22	24	24	21	22
Total Malignant Neoplasms	29	26	31	35	21	22
Total Animals with Metastatic Neoplasms	1	3	6	2	4	2
Total Metastatic Neoplasms	1	7	22	12	6	2
Total Animals with Malignant Neoplasms Uncertain Primary Site				1		
Total Animals with Neoplasms Uncertain- Benign or Malignant						
Total Uncertain Neoplasms						

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors